Anion-Exchange Membrane Adsorber Patents: Who Leads, Gaps 2026
- One assignee holds the field. of the 14 ranked companies, the leader accounts for 75 of the tracked records, while fifth and tenth place each sit at just 2 — a steep drop-off, not a gradual one.
- Filing peaked in 2017 at 43 records and the tracked growth figure shows a -100% change from 2021 (2 records) to 2024 (0), the last year treatable as complete given publication lag.
- Every record touches peptide and protein chemistry. C07K covers 100% of the 90 records in scope, while separation-process claims under B01D appear in only 14.4% — the hardware side of the field is comparatively thin.
Filing growth compares 2021 (2 records) with 2024 (0) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
What this landscape covers
Anion-exchange membrane adsorbers sit at the intersection of membrane separation engineering and downstream biopharmaceutical purification. Instead of packing a column with resin beads, the stationary phase is a functionalised membrane, which cuts diffusion path lengths and lets flow-through polishing steps run at higher volumetric rates. This dataset isolates patent activity that names anion-exchange membrane adsorbers specifically for protein purification, membrane chromatography or biopharmaceutical processing, and excludes water-treatment and analytical-assay filings that use similar membrane hardware for unrelated purposes.
The 90 records in scope span 2015 through the 2026 cut-off, filed through receiving offices concentrated in Israel, Europe and the United States. Because publication lags filing by roughly 18 months, the apparent decline after 2021 partly reflects records still working through the pipeline rather than a confirmed drop in filing activity.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 90-record dataset: filing activity over time, and how records distribute across IPC subclasses. Because a single record can carry more than one IPC class, the composition shares add up to more than 100%.
Filing trend, 2017–2026
Filings peaked at 43 in 2017 and the tracked growth window shows 2021 (2 records) falling to 2024 (0), a -100% change over that three-year span. Treat 2025 and 2026 as incomplete rather than as evidence of a further decline, since publication lag means recent filings have not all surfaced yet.
IPC subclass composition
C07K (peptides and proteins) appears in all 90 records in scope, confirming this is fundamentally a protein-chemistry claim set. B01D (separation processes) reaches 14.4% of records, C12N (microorganisms and genetic engineering) 13.3%, B01J (catalysis-adjacent chemical processes) 6.7%, and A23J (food-related proteins) a single record at 1.1%.
Shares are the percentage of the 90 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Membrane Chromatography — Anion-Exchange Membrane Adsorbers Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about membrane chromatography — anion-exchange membrane adsorbers patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this dataset
US20190153028A1 — Method for protein purification
The present invention provides a method for manufacturing antibodies or a fragment thereof with reduced levels of antibody reduction related impurities.Filed by UCB Biopharma, published 2019-05-23.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2017140881A1 | Protein purification | 20 |
| 2 | WO2019016154A1 | chromatography | 13 |
| 3 | US20120009650A1 | Compositions, methods and kits for preparing plasminogen and plasmin prepared therefrom | 10 |
| 4 | US20200331960A1 | chromatography | 6 |
| 5 | US20190153028A1 | Method for protein purification | 4 |
| 6 | WO2010101903A2 | Compositions, methods and kits for preparing plasminogen; and plasmin prepared therefrom | 3 |
| 7 | AU2017220675A1 | Protein purification | 2 |
| 8 | EP3730511A1 | Protein purification | 2 |
| 9 | US11498941B2 | Chromatography | 1 |
| 10 | US20190202859A1 | Protein purification | 1 |
Citation counts inside a searched corpus favour older filings that have had more time to accumulate references — read them as a signal of influence within this dataset, not as a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
The dataset points to a field with one dominant filer, a claim set almost entirely anchored in protein chemistry, and hardware-level separation claims that remain comparatively open.
One filer dominates the ranking
The top-ranked assignee accounts for 75 records against a fifth-place figure of just 2, meaning the field is not evenly contested — it is one large portfolio surrounded by a long tail of much smaller filers and individual inventors.
Recent filing has thinned, with the caveat of publication lag
The tracked growth figure moves from 2 records in 2021 to 0 in 2024, the last year treatable as complete. Years after 2024 are still filling in due to the roughly 18-month gap between filing and publication, so this should not be read as the field ending.
Protein chemistry is the universal claim element
Every record in scope carries a C07K classification, confirming that anion-exchange membrane adsorber claims in this space are consistently tied to peptide and protein composition or purification methods rather than filed as pure separation hardware.
Filing offices skew toward Israel and Europe
Israel leads receiving-office counts at 12, ahead of the European Patent Office at 11 and the United States at 9, with Australia, Germany and India each at 4 — a distribution worth checking before assuming US filing is the default route in this niche.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to membrane chromatography — anion-exchange membrane adsorbers patent landscape, with the prior art for and against each one.
Who is filing, and where the claim space is still open
The ranking is short and top-heavy: a single company holds the bulk of the tracked records, while most of the remaining named entities appear as individual inventors rather than corporate portfolios. Momentum data shows zero recent-year filings across every tracked name, consistent with the publication-lag effect described above rather than a confirmed stop in activity.
A single dominant portfolio
One assignee's record count separates it clearly from every other name in the ranking, suggesting a company that has built a defensive filing position around anion-exchange membrane adsorber methods over the tracked period rather than one that files opportunistically.
Individual inventors fill out the ranking
Beyond the leader, record counts flatten quickly — fifth and tenth place both sit at 2 records — and several ranked names are individual inventors rather than corporate assignees, pointing to a field where smaller players file narrowly scoped, specific claims.
Collaboration is limited and concentrated
Ten co-assignee pairings appear in the dataset, with the strongest repeated pairings both linked to the same corporate assignee working alongside named individual inventors — a pattern consistent with in-house R&D teams rather than cross-company joint filings.
| Assignee | Recent year | YoY |
|---|---|---|
| UCB Biopharma | 0 | — |
| Talecris Biotherapeutics | 0 | — |
| Grifols Therapeutics | 0 | — |
| ZIMMERMAN THOMAS P | 0 | — |
| YUSB BIOFARMA SRL | 0 | — |
| STOKES KENYA | 0 | — |
| SILVERSTEIN REBECCA | 0 | — |
| REBBEOR JAMES | 0 | — |
Where to take this analysis
The dataset flags concentration and composition; the next step is testing specific claim language against the leader's portfolio and the most-cited records before committing to a filing direction.
Check freedom-to-operate against the leading portfolio
With one assignee holding 75 of the 90 ranked records, any new filing in membrane adsorber methods should be checked against that portfolio's claim scope first, rather than against the field average.
Run a claim comparison in EurekaTest draft claims in the under-claimed branches
B01D and B01J classes remain comparatively thin relative to the universal C07K coverage, which is where a narrowly drafted hardware or catalysis-adjacent claim is less likely to collide with existing filings.
Explore white space in EurekaCommon questions on anion-exchange membrane adsorber patents
It is a flow-through purification step that replaces resin-packed columns with a functionalised membrane for removing negatively charged impurities such as host-cell DNA, endotoxin and certain process-related proteins from a biologic drug product. Because the membrane format has a much shorter diffusion path than packed resin beads, it can run at higher volumetric flow rates during polishing steps. In this dataset, every record carries a C07K peptide/protein classification, confirming these filings are consistently framed around protein purification methods rather than filed as standalone separation hardware.
The ranking in this dataset is led by one assignee with 75 of the tracked records, far ahead of the rest of the 14 companies ranked — fifth and tenth place both sit at just 2 records each. This is a steep concentration rather than a gradual decline, meaning most competitive activity in this niche is effectively defined by one company's filing history. The remaining ranked names include several individual inventors rather than corporate portfolios.
The tracked growth figure shows a fall from 2 records in 2021 to 0 in 2024, a -100% change, with 2017 as the historical peak at 43 records. However, publication typically lags filing by around 18 months, so 2025 and 2026 records are still incomplete in this dataset and should not be read as confirmation that filing has stopped. The 2024 figure is the most recent one that can be treated as a complete year.
US20190153028A1, filed by UCB Biopharma and published 2019-05-23, describes a method for manufacturing antibodies or antibody fragments with reduced levels of antibody-reduction-related impurities. It is among the most-cited records in this dataset, sitting alongside other frequently cited filings on protein purification and chromatography. Anyone drafting a purification method claim in this space should review its specific process steps directly, since citation counts alone only indicate influence within the searched corpus, not the current scope of enforceable claims.
IPC composition shows B01D (separation processes) at 14.4% of the 90 records and B01J (catalysis-adjacent chemical processes) at just 6.7%, both far behind the near-universal C07K protein-chemistry coverage. That gap suggests hardware-level claims — membrane pore-size functionalization, flow-through step integration, or multi-modal surface chemistry — are comparatively under-claimed relative to the composition and method claims that dominate the field. A first claim in these branches would need to be checked against the leading assignee's portfolio before filing, given how concentrated the overall ranking is.
Research Membrane Chromatography — Anion-Exchange Membrane Adsorbers Patent Landscape in depth with Eureka
Go past this page: query the whole membrane chromatography — anion-exchange membrane adsorbers patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.